Lisa Marie Gentry
Family · Philadelphia, PANPI 1861414351
Payments from drug & device makers
Across 171 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$710
- Amgen$457
- AstraZeneca$323
- AbbVie$234
- Lilly USA, LLC$186
- Exact Sciences$151
- plus $851 from 20 others
What the payments were for
- Food & beverage$2,912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $710 |
| Amgen | 26 | $457 |
| AstraZeneca | 20 | $323 |
| AbbVie | 19 | $234 |
| Lilly USA, LLC | 9 | $186 |
| Exact Sciences | 8 | $151 |
| Amarin Pharma, Inc. | 8 | $113 |
| Pfizer | 7 | $111 |
| Merck | 6 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Bayer | 3 | $63 |
| Boehringer Ingelheim | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Vertos Medical, Inc. | 1 | $32 |
| Abbott | 2 | $27 |
| Astellas Pharma US Inc | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Althera Pharmaceuticals LLC | 1 | $18 |
| GSK | 1 | $18 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| Novartis | 1 | $13 |
How this compares
$2,912 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 18 | $22,477 |
| EliquisApixaban | 22 | $20,317 |
| FarxigaDapagliflozin Propanediol | 13 | $19,290 |
| MounjaroTirzepatide | 17 | $17,838 |
| Bydureon BciseExenatide Microspheres | 12 | $9,767 |
| LinzessLinaclotide | 14 | $7,546 |
| Repatha SureclickEvolocumab | 12 | $6,632 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,618 |
| Atorvastatin Calcium | 340 | $5,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $3,104 |
| Levothyroxine Sodium | 233 | $2,627 |
| Fluticasone Propionate | 114 | $2,439 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,109 |
| Rosuvastatin Calcium | 100 | $2,084 |
| Losartan Potassium | 152 | $1,874 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $97 | $22,47718 claims |
| PfizerEliquis | $111 | $20,31722 claims |
| AstraZenecaFarxiga | $323 | $19,29013 claims |
| Lilly USA, LLCMounjaro | $186 | $17,83817 claims |
| AbbVieLinzess, Synthroid | $234 | $8,43234 claims |
| Boehringer IngelheimSpiriva Respimat | $57 | $6,61813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Philadelphia
- Bethany ThomasPhiladelphia$126K
- Anne CalvaresiPhiladelphia$81K
- Bethany MooneyPhiladelphia$73K
- Susan Estrella-EadesPhiladelphia$61K
- Michelle Vega-OlivoPhiladelphia$55K
- Danielle LandPhiladelphia$48K
- Nicole SmithPhiladelphia$37K
- Dana SerafinPhiladelphia$31K
- Tammaris KaschakPhiladelphia$27K
- Laura NoltePhiladelphia$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.